Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.36 |
| ▸ | CDK4 | P11802 | 2/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.34 |
| ▸ | CCND1 | P24385 | 2/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | CCND3 | P30281 | 2/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 6/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19402046 | 1.00 | TRPV1 (0.36) | TRPV1CDK4CCNA2CCND1CCNE1 | |
| SCHEMBL20676949 | 0.80 | IDH1 (0.31) | IDH1 | |
| SCHEMBL19402040 | 0.80 | IDH1 (0.31) | IDH1 | |
| SCHEMBL20956364 | 0.79 | CDK4 (0.47) | TRPV1CDK4CCNA2CCND1CCNE1 | |
| SCHEMBL20677047 | 0.78 | HDAC6 (0.47) | TP53MDM2IDH1 | |
| SCHEMBL19402044 | 0.78 | HDAC6 (0.47) | TP53MDM2IDH1 | |
| SCHEMBL23019766 | 0.76 | TRPV1 (0.33) | TRPV1CDK4CCNA2CCND1CCNE1 | |
| SCHEMBL19402112 | 0.76 | CDK4 (0.50) | CDK4CCNA2CCND1CCNE1CDK2 | |
| SCHEMBL20677090 | 0.76 | CDK4 (0.50) | CDK4CCNA2CCND1CCNE1CDK2 | |
| SCHEMBL16098324 | 0.70 | ROCK1 (0.37) | TRPV1CDK4CCNA2CCND1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3434674-B1 | ((4-(2-OXOIMIDAZOLIDINE-1-YL)PYRIMIDIN-2-YL)AMINE DERIVATIVES AS MUTANT IDH INHIBITORS FOR TREATING CANCER | SHANGHAI HAIHE PHARMACEUTICAL CO LTD (CN) | 2021-02-24 | — | — | EP | disclosed |
| US-10682352-B2 | Compound having mutant IDH inhibitory activity, preparation method and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-10682352-B2 | Compound having mutant IDH inhibitory activity, preparation method and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-20190111056-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-18 | — | — | US | disclosed |
| US-20190111056-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-18 | — | — | US | disclosed |
| EP-3434674-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2019-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111056-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | IDH1, IDH3A, IDH2 | TRPV1 4467/4885CDK4 2218/4885CCNA2 4143/4885 |
| US-10682352-B2 | Compound having mutant IDH inhibitory activity, preparation method and use thereof | IDH1, IDH3A, IDH2 | TRPV1 4467/4885CDK4 2218/4885CCNA2 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.